Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


ANIKA THERAPEUT   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2021202020192018201720162015201420132012
Period End Date12/31/202112/31/202012/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/2012
Product revenue147.79130.46114.61105.53107.78102.9387.7075.4771.7768.01
Licensing, milestone and contract revenue------0.025.640.455.3030.123.313.35
Total Revenues147.79130.46114.61105.56113.42103.3893.00105.6075.0871.36
Cost of product revenue64.8561.4328.7531.2827.3624.0321.0520.9322.7728.99
Gross Profit82.9469.0385.8674.28------------
Goodwill impairment--42.52----------------
Research & development27.3323.4316.6718.1918.7910.738.998.147.065.39
Selling, general & administrative74.1060.0634.9534.3421.5418.0114.8315.0712.9414.73
Restructuring charges----------------(0.29)2.54
Acquisition-related expenses--------------------
Litigation settlement costs--------------------
Change in fair value of contingent consideration21.1028.67----------------
Total Operating Expenses80.3397.3551.6252.5367.6952.7744.8744.1542.4751.64
Operating Income (Loss)2.62(28.32)34.2521.7545.7350.6148.1361.4532.6119.72
Gain on sale of securities--------------------
Interest income, net(0.19)(0.30)1.871.460.470.260.120.06(0.13)(0.19)
Income (loss) before income taxes2.43(28.62)36.1223.2146.2050.8748.2561.5132.4819.53
Current: Federal0.490.366.254.7812.6114.9814.5718.308.027.59
Current: State(0.64)(1.97)1.881.642.743.273.643.901.580.89
Provision for income taxes(1.71)(4.64)8.934.4914.3918.3217.5023.1911.917.77
Deferred: Federal(0.55)(1.98)1.09(0.99)(0.43)(0.07)(0.37)1.152.380.78
Deferred: State(0.43)(1.07)0.32(0.15)(0.07)(0.08)(0.03)0.120.120.60
Deferred: Foreign(0.75)(0.03)(0.81)(1.20)(0.50)(0.07)(0.56)(0.48)(0.28)(1.90)
Current- Foreign0.170.050.200.410.030.300.250.190.09(0.19)
Benefit from release of valuation allowance--------------------
Benefit from release of valuation allowance: Federal--------------------
Benefit from release of valuation allowance: State--------------------
Income Before Extraordinary Income & Accounting Change--------------------
Cumulative effect of change in accounting principle--------------------
Net Income (Loss) Available to Common Shareholders4.13(23.98)27.1918.7231.8232.5530.7638.3220.5811.76
Basic: Income (loss) before cumulative effect of change in accounting principle--------------------
Basic: Cumulative effect of change in accounting principle--------------------
Basic net income per share0.29(1.69)1.931.302.182.222.062.611.460.89
Diluted: Income (loss) before cumulative effect of change in accounting principle--------------------
Diluted: Cumulative effect of change in accounting principle--------------------
Diluted net income per share0.28(1.69)1.891.272.112.152.012.511.390.82
Basic weighted average common shares outstanding14.4014.2214.1214.4414.5814.6814.9314.6814.0913.26
Diluted weighted average common shares outstanding14.6314.2214.3714.6915.0715.1215.3215.2714.8314.34